Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lymphocyte transformation was studied in 24 patients with ankylosing spondylitis (AS), 21 with rheumatoid arthritis (RA) and 23 control subjects (CS). Enhanced transformation was found in response to phytohemagglutinin (PHA) (p less than 0.01) and human aggregated gamma globulin (p less than 0.025), but not to inulin, for AS patients. Correlation coefficients between the concentrations of each of 8 AS plasma proteins and PHA-induced lymphocyte transformation in autologous plasma showed significance only for C-reactive protein (CRP). However, co-culture experiments with PHA in autologous and allogeneic (AB) plasma, and in CRP-devoid AB serum showed no specific enhancing effect by AS plasma on lymphocyte responses. Although these studied demonstrate that AS is frequently characterized by enhanced in vitro transformation to T lymphocyte dependent mitogens, this response does not appear to be related to the known immunoregulatory properties of CRP.
 ...
PMID:Correlative studies of lymphocyte transformation and plasma protein levels in ankylosing spondylitis. 52 47

In an open study, a new treatment modality was evaluated in 22 patients with active ankylosing spondylitis and compared with oral treatment. Patients were given a 10-week course of rifamycin SV infiltrations to all large peripheral joints, whether or not affected, and were followed for up to 12 months after the end of treatment. Clinical improvements observed at the end of the 10-week treatment cycle persisted for 12 months: morning stiffness (P less than 0.02); subjective pain (P less than 0.0001); Schober's test (P less than 0.006); hand-ground distance (P less than 0.001); erythrocyte sedimentation rate (P less than 0.001); and C-reactive protein (P less than 0.04). The number of painful joints became significantly lower at 6 (P less than 0.01) and 12 months (P less than 0.02) of the follow-up period. Oral administration of rifampin at three times the intra-articular dosage was devoid of any therapeutic activity. It is not known how treatment of peripheral joints influenced the inflammatory process at the level of the axial skeleton. These results must be considered preliminary due to the small number of patients and the short follow-up period, and because it was an open study.
 ...
PMID:Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints. 152 73

An enzyme-linked immunoassay detecting soluble CD8 (s-CD8) was applied to study activation of CD8(+)-(suppressor/cytotoxic) T-cells in patients with rheumatic diseases. Compared with normals, s-CD8 levels were elevated in patients with rheumatoid arthritis, ankylosing spondylitis, and polymyositis. In contrast, low s-CD8 values were observed in patients with progressive systemic sclerosis/scleroderma. In systemic lupus erythematosus (SLE), s-CD8 values were correlated with C-reactive protein. This finding and an association with other parameters of clinical activity were confirmed by longitudinal studies. In summary, our findings support the view that implication of CD8(+)-T-cell activation is different in the pathogenesis of each rheumatic disease. Elevated s-CD8 indicates active disease, and can be used to monitor CD8(+)-T-cell activation in SLE while determination of s-CD8 seems to be of little clinical value in the other rheumatic diseases studied.
 ...
PMID:[Circulating CD8 as an indicator of inflammatory rheumatic disease]. 156 57

In a 12-month double-blind placebo-controlled trial, the effect of sulphasalazine was studied in 40 patients with ankylosing spondylitis. The treatment group showed significant improvement in pain, stiffness, sleep disturbance (p less than 0.05), finger/floor distance, erythrocyte sedimentation rate, C-reactive protein, orosomucoid and IgA levels (p less than 0.01). There was improvement in sleep disturbance (p less than 0.05), finger/floor distance and erythrocyte sedimentation rate (p less than 0.01) in the placebo group. Sulphasalazine did not retard radiological progression as measured either by plain X-ray or computerised tomographic scans. Multiple analysis of variance did not show a significant difference in disease activity indicators between the 2 groups.
 ...
PMID:Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. 167 21

Freshly isolated peripheral blood mononuclear cells (PBMC) from 10 healthy volunteers, 28 patients with rheumatoid arthritis (RA), eight patients with osteoarthritis, and five patients with ankylosing spondylitis were examined for interleukin-1 alpha (IL-1 alpha) and interleukin-1 beta (IL-1 beta) production using monoclonal antibodies and an indirect immunofluorescent method. In freshly isolated PBMC from healthy controls very few cells were stained for either IL-1 type. All 20 RA patients who were not receiving parenteral gold therapy had PBMC staining for IL-1 alpha. In these patients, up to 7.5% of PBMC showed bright IL-1 alpha staining (range 1.2-7.5%). No IL-1 beta staining was seen. These IL-1 alpha-staining cells had a dendritic morphology and the percentage of cells staining correlated well with levels of C-reactive protein, an index of disease activity in these RA patients. Significantly fewer IL-1 alpha-staining cells were present in the peripheral blood of RA patients receiving gold therapy and in the blood of patients with osteoarthritis and ankylosing spondylitis. These IL-1 alpha-containing cells, circulating in the blood of RA patients and correlating with disease activity have not been previously described. These results support the idea that IL-1 alpha plays an important role in the pathogenesis of rheumatoid inflammation.
 ...
PMID:Cells with dendritic morphology and bright interleukin-1 alpha staining circulate in the blood of patients with rheumatoid arthritis. 196 79

Prealbumin was shown to be a sensitive indicator of disease activity in a prospective study of 21 patients with active ankylosing spondylitis (AS) who were treated with 3 intravenous pulses of methylprednisolone and its concentration was found to change at a different rate to C-reactive protein (CRP). In those diseases in which CRP concentration rises with active disease, i.e., rheumatoid arthritis, AS and Crohn's disease, prealbumin fell, but in those diseases in which CRP rises only slightly, i.e., systemic lupus erythematosus, progressive systemic sclerosis and ulcerative colitis, there was nevertheless a fall in serum prealbumin, indicating that there was an acute phase response occurring. Fever, arthritis and infection were the only disease manifestations that were associated with an elevated CRP in both groups of diseases. There is therefore more than one signal for an acute phase response depending on the nature of the disease pathology.
 ...
PMID:Is there more than one signal for an acute phase response? 241 56

Disease activity was assessed clinically and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), orosomucoid, alpha 1-antitrypsin (alpha 1AT) and alpha 2-macroglobulin (alpha 2M) were measured in 65 patients with ankylosing spondylitis (AS). Positive correlations were found between ESR and the acute phase proteins (APP), CRP, orosomucoid and alpha 1AT, but none of these variables correlated with the clinical assessment of activity. No relationship was demonstrated between the protease inhibitor, alpha 2M and clinical activity, ESR or any of the APP. While the treatment of AS remains predominantly symptomatic, routine management of patients should continue to be founded on the clinical assessment of disease activity rather than on laboratory indices of inflammation.
 ...
PMID:Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. 242 77

Eighty-five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine (less than or equal to 3 gm/day, mean 2.5) or placebo for 26 weeks. There was a statistically significant improvement, compared with baseline, in most of the clinical variables in patients receiving the active drug. Laboratory parameters (erythrocyte sedimentation rate, C-reactive protein, IgG, IgM, and IgA) also improved during the active treatment, suggesting a beneficial effect of sulfasalazine on AS. At the end of the treatment, significant differences between the sulfasalazine and placebo groups were observed in morning stiffness, chest expansion, erythrocyte sedimentation rate, and in all immunoglobulin classes. Two patients in each treatment group discontinued the trial because of side effects. Enteric-coated sulfasalazine seemed to be effective and well tolerated in patients with active AS.
 ...
PMID:Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. 290 39

Using radial immunodiffusion in 7% agarose, 7S IgM was quantified in the sera of 45 normal individuals, 37 patients with rheumatoid arthritis (RA), 18 patients with psoriatic arthritis and 11 patients with ankylosing spondylitis. 7S IgM was only found in the sera of patients with RA, 43% of whom had detectable levels of 7S IgM (median 47.5 micrograms/ml). The patients with 7S IgM had significantly higher IgM rheumatoid factor (IgM RF) and C-reactive protein levels in their sera (p less than 0.005). There was a strong correlation between 7S IgM and IgM RF levels in the sera of these patients. These data demonstrate that patients with more active and severe disease have 7S IgM present in their sera but the absence of 7S IgM from the sera of some patients with high levels of IgM RF and CRP suggest that additional factors may influence the synthesis and secretion of 7S IgM by B cells in RA.
 ...
PMID:7S IgM in the sera of patients with arthritis. 310 8

Forty-four patients, 22 with ankylosing spondylitis (AS) and 22 with Reiter's syndrome (RS) were studied to determine the reliability of C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR) as indicators of disease activity. CRP levels were significantly elevated in patients with active disease for both AS and RS while ESR values for active and inactive disease were not statistically different. Misdiagnosis was more likely when ESR rather than CRP was used as the variable for activity. CRP as measured by nephelometry is a more sensitive and specific indicator of disease activity in AS and RS than ESR.
 ...
PMID:C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome. 372 98


1 2 3 4 5 6 7 8 9 10 Next >>